Here are the 8-K filings from Surrozen, Inc. (SRZN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow SRZN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRZN filings page.
Surrozen, Inc. (SRZN) completed the second and final tranche of its March 2025 private placement on October 20, 2026, generating approximately $95.1 million in gross proceeds before placement agent fees and other expenses. The closing issued 5,741,605 common shares, pre-funded warrants exercisable for 2,456,500 shares, and Series E warrants to purchase 4,099,052 shares. The common-share purchase price was $11.60, and Series E warrants carry an $11.54 exercise price.
Following closing, Surrozen reported approximately 17.8 million common shares outstanding, 3.8 million shares issuable upon exercise of pre-funded warrants, and 9.1 million shares issuable upon exercise of outstanding common stock warrants. It expects cash, cash equivalents and marketable securities to provide runway into 2029, including funding for completion of the SZN-8141 DUET Phase 1b/2a study and initial Phase 1b development of SZN-8143. First patient dosing in DUET is expected in the fourth quarter of 2026, with initial data expected in the second half of 2027. Surrozen agreed to file a resale registration statement within 30 calendar days after closing and use reasonable best efforts to have it declared effective promptly, and no later than 90 calendar days (or 120 calendar days after a full SEC review).
Surrozen, Inc. (SRZN) announced FDA clearance of the IND for SZN-8141, allowing the program to advance into clinical development. The IND became effective after the statutory 30-day review. SZN-8141 is a bifunctional Wnt agonist and vascular endothelial growth factor antagonist antibody being developed as an intravitreal injection for diabetic macular edema. Surrozen expects to dose the first patient in the DUET Phase 1b/2a study in the fourth quarter of 2026, with initial data expected in the second half of 2027.
The clearance satisfies the second closing milestone under Surrozen's March 2025 two-tranche private placement. The second closing is expected to provide approximately $95.1 million in gross proceeds, before placement agent fees and other expenses, and is expected on or about October 20, 2026, subject to applicable closing conditions. Proceeds are expected to support SZN-8141, SZN-8143 and broader operating activities. After closing, Surrozen expects to file an S-3 resale registration for common shares and shares issuable upon exercise of pre-funded and Series E common stock warrants; the registration rights agreement requires filing no later than 30 calendar days following closing.
Surrozen reported Q2 2026 results and updated its ophthalmology pipeline. Collaboration and license revenue was $5.0 million, driven by a milestone from Boehringer Ingelheim. Research and development expenses were $8.5 million and general and administrative expenses $6.9 million. Net income was $50.2 million, including $59.6 million of non-cash gains on tranche and warrant liabilities. Cash and cash equivalents were $102.0 million as of June 30, 2026.
The company plans to submit an IND for SZN-8141 by the end of the third quarter of 2026, initiate the DUET Phase 1b/2a study in diabetic macular edema by year-end 2026, and expects initial DUET data in the second half of 2027. In June 2026 Boehringer Ingelheim achieved a development milestone for SZN-413, and in July 2026 the U.S. Patent Trial and Appeal Board denied institution of Merck’s post-grant review petition challenging a Surrozen patent, reinforcing its intellectual property position.
Surrozen, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of 11,486,707 shares entitled to vote as of March 18, 2026, 7,744,669 were represented in person or by proxy. Stockholders elected Mace Rothenberg, M.D., and David J. Woodhouse, Ph.D., as Class II directors until the 2029 Annual Meeting, subject to earlier departure. They also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. On an advisory basis, stockholders approved the compensation of the named executive officers and chose to hold future advisory votes on executive compensation every year.
Surrozen reported first quarter 2026 results that pair advancing eye-disease programs with heavy non-cash losses tied to financing structures. The company is progressing lead retinal candidates SZN-8141 and SZN-8143 and remains on track to submit an Investigational New Drug application for SZN-8141 in the second half of 2026.
Collaboration and license revenue was $5.0 million, driven by a Boehringer Ingelheim milestone for SZN-413, while cash and cash equivalents rose to $106.9 million as of March 31, 2026 from $89.2 million at year-end. Research and development expenses increased to $9.3 million and general and administrative expenses to $6.1 million as the ophthalmology portfolio scales up.
Net loss widened sharply to $127.5 million, or ($11.65) per share, compared with $27.0 million, or ($7.43) per share, a year earlier. The larger loss primarily reflects a $76.9 million non-cash loss on change in fair value of tranche liability related to the 2025 PIPE and a $41.1 million other expense, mainly from an $81.7 million non-cash increase in warrant liabilities. As of March 31, 2026, tranche liability was $235.5 million and warrant liabilities were $148.9 million, contributing to a stockholders’ deficit of $278.1 million.
Surrozen reported a much larger 2025 net loss but ended the year with significantly more cash and a sharper focus on ophthalmology. Net loss widened to $242.0 million, or ($32.37) per share, from $63.6 million, largely due to non-cash losses tied to a 2025 private placement and related tranche and warrant liabilities.
Cash and cash equivalents rose to $89.2 million as of December 31, 2025, up from $34.6 million a year earlier, helped by equity sales and warrant exercises in early 2026. Total 2025 revenue was $3.5 million, down from $10.7 million, while research and development and general and administrative expenses increased to $29.4 million and $16.2 million, respectively. The company advanced retinal programs SZN-8141 and SZN-8143, expects to file an IND for SZN-8141 in the second half of 2026, and earned a $5.0 million milestone from Boehringer Ingelheim under the SZN-413 partnership, which also includes up to $586.5 million in potential future milestones.
Surrozen, Inc. reported that board member Shao-Lee Lin, M.D., Ph.D. resigned from its Board of Directors, effective immediately on January 26, 2026. The company stated that Dr. Lin’s resignation was not due to any disagreement regarding Surrozen’s operations, policies, or practices. Surrozen expressed appreciation for her service and dedication to the company’s mission.
Surrozen (SRZN) appointed Andrew Maleki as Chief Financial Officer, effective November 12, 2025, and furnished a press release with results for the quarter ended September 30, 2025.
Maleki’s offer includes a base salary of $385,000, an annual bonus target of 40% of base salary starting in 2026, and a stock option for 50,000 shares vesting 25% after one year, then monthly in equal installments over the next three years. If terminated without cause, he is eligible for nine months of base salary and benefits. If terminated in connection with a change in control, he is eligible for 12 months of base salary, 100% of target bonus, 12 months of benefits, and full equity vesting.
Charles Williams will cease serving as CFO and continue as Chief Operating Officer and Secretary.
Surrozen, Inc. (SRZN) reported that TCGFB, Inc. elected to terminate their Collaboration Agreement. The notice was delivered on October 14, 2025, with termination effective November 13, 2025, and no termination penalties for either party.
Under the agreement, Surrozen provided antibody discovery services while TCGFB owned all TGF-β product intellectual property. In return, TCGFB agreed to pay Surrozen up to $6.0 million in the aggregate, plus third-party costs, and issued a warrant exercisable for up to 3.4 million TCGFB common shares at an exercise price of $0.0001 per share, subject to vesting conditions.
The arrangement was a related party transaction because entities affiliated with The Column Group hold more than 5% of Surrozen’s common stock and Dr. Kutzkey, a Surrozen director, serves as Managing Partner of The Column Group.